Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg

NCT00649272 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Oxybutynin Chloride Extended-Release Tablets, 15 mg
DRUG: Ditropan XL® Extended-release tablets, 15 mg

Sponsor

Mylan Pharmaceuticals Inc